CN102912007A - CYP2B6 gene polymorphism detection specific primers and liquid chip - Google Patents
CYP2B6 gene polymorphism detection specific primers and liquid chip Download PDFInfo
- Publication number
- CN102912007A CN102912007A CN2011102192445A CN201110219244A CN102912007A CN 102912007 A CN102912007 A CN 102912007A CN 2011102192445 A CN2011102192445 A CN 2011102192445A CN 201110219244 A CN201110219244 A CN 201110219244A CN 102912007 A CN102912007 A CN 102912007A
- Authority
- CN
- China
- Prior art keywords
- seq
- site
- sequence
- comprised
- tag sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses CYP2B6 gene detection specific primers and a liquid chip. The liquid chip mainly comprises: various ASPE primers composed of 5' terminal tag sequence and 3' terminal specific primer sequences aiming at target gene mutation site, microspheres coated with anti-tag sequence, and amplification primers. The specific primer sequences comprise: SEQ ID NO.13 and SEQ ID NO.14 aiming at C123T site; SEQ ID NO.15 and SEQ ID NO.16 aiming at A101G site; SEQ ID NO.17 and SEQ ID NO.18 aiming at G118T site; SEQ ID NO.19 and SEQ ID NO.20 aiming at A77G site; SEQ ID NO.21 and SEQ IDNO.22 aiming at T139C site; and/or SEQ ID NO.23 and SEQ ID NO.24 aiming at C288T site. The matching rate of the detection result obtained by using the liquid chip provided by the invention and a result obtained by using a sequencing method is 100%. Therefore, wild-type and mutant-type parallel detections of a plurality of mutation sites are realized.
Description
Technical field
The invention belongs to biology field, relate to medical science and biotechnology, concrete a kind of CYP2B6 gene pleiomorphism detection specificity primer and the liquid-phase chip of relating to.
Background technology
CYP2B6 is drug metabolism enzyme important in the CYP family, be distributed widely in human liver, kidney, lung, small intestine, uterine endometrium, BA scavenger cell, peripheral blood lymphocyte and brain etc. participate in the synthetic and metabolism of multiple endogenous and exogenous material.The CYP2B6 assignment of genes gene mapping is in 19q12～13.2, and total length 28kb is separated 9 exons by 8 introns, and the protein of coding is comprised of 491 amino acid, and relative molecular mass is 58268.There are some researches show that the CYP2B6 protein expression level and exists difference not only between the race between different sexes, individual difference surpasses 250 times, even some people's expression can't detect.The principal element that causes CYP2B6 to express individual difference is h and E, known CYP2B6 can be suppressed by multi-medicament and induce, in addition, numerous gene pleiomorphisms also are found, and the factors such as race, sex, age are all influential to CYP2B6 expression and activity.
The CYP2B6 gene mutation site (pleomorphism site) of target detect of the present invention, it is as shown in the table:
| Sequence number | The content of CYP2B6 site mutation | Write a Chinese character in simplified form |
| 1 | C → T sudden change occurs in the 123rd Nucleotide of SEQ ID NO.55 | C123T |
| 2 | A → G sudden change occurs in the 101st Nucleotide of SEQ ID NO.56 | A101G |
| 3 | G → T sudden change occurs in the 118th Nucleotide of SEQ ID NO.57 | G118T |
| 4 | A → G sudden change occurs in the 77th Nucleotide of SEQ ID NO.58 | A77G |
| 5 | T → C sudden change occurs in the 139th Nucleotide of SEQ ID NO.59 | T139C |
| 6 | C → T sudden change occurs in the 288th Nucleotide of SEQ ID NO.59 | C288T |
At present, the method that the CYP2B6 gene pleiomorphism is detected, analyzes mainly contains: direct sequencing and PCR-RFLP analytical method etc., wherein the most frequently used method has the PCR-RFLP analytical method.The PCR-RFLP method is based on the change of the restriction enzyme enzyme recognition site that transgenation causes, as losing or produce novel site in the site, by a certain specific fragment of pcr amplification, use again the digestion with restriction enzyme amplified production, the size of electrophoresis observation fragment, this method can directly be judged genotype for detection of the transgenation that restriction enzyme site changes, but this method can not be used for not producing the detection in Gene Mutation of new restriction enzyme site.Again, more than these methods all exist the limitation that detects flux, can only detect a kind of mutation type at every turn, can not satisfy the needs of practical application.
Summary of the invention
One of purpose of the present invention provides the CYP2B6 gene pleiomorphism and detects liquid-phase chip, and this liquid-phase chip can be used for detecting wild-type and the mutant of CYP2B6 gene six kinds of common genotype C123T, A101G, G118T, A77G, T139C and C288T.
The technical scheme that realizes above-mentioned purpose is as follows:
A kind of CYP2B6 gene pleiomorphism detects liquid-phase chip, includes:
(A). the wild-type that designs respectively for the different pleomorphism sites of CYP2B6 gene and the ASPE primer of mutant pair: every ASPE primer is comprised of the tag sequence of 5 ' end and 3 ' the end specific primer sequence for the goal gene pleomorphism site, and described specific primer sequence is: for SEQ ID NO.13 and the SEQ ID NO.14 in C123T site; SEQ ID NO.15 and SEQ ID NO.16 for the A101G site; SEQ ID NO.17 and SEQ ID NO.18 for the G118T site; SEQ ID NO.19 and SEQ ID NO.20 for the A77G site; SEQ ID NO.21 and SEQ ID NO.22 for the T139C site; And/or for SEQ ID NO.23 and the SEQ ID NO.24 in C288T site; Described tag sequence is selected from SEQ ID NO.1～SEQ IDNO.12;
(B). anti-tag sequence microballoon coated, that have the different colours coding is arranged, also be provided with the spacerarm sequence in the middle of described anti-tag sequence is connected with microballoon; Described anti-tag sequence is selected from SEQ ID NO.25～SEQ ID NO.36, and described anti-tag sequence can be correspondingly with (A) in selected tag sequence complementary pairing;
(C). be used for amplifying the primer that needs target sequence detection, that have corresponding pleomorphism site.
Preferably, described amplimer is: for SEQ ID NO.37 and the SEQ ID NO.38 in C123T site; SEQ ID NO.39 and SEQ ID NO.40 for the A101G site; SEQ ID NO.41 and SEQ ID NO.42 for the G118T site; SEQ ID NO.43 and SEQ ID NO.44 for the A77G site; And/or for SEQ ID NO.45 and the SEQ ID NO.46 in T139C, C288T site.
Preferably, described ASPE primer is: the sequence that is comprised of SEQ ID NO.1 and SEQ ID NO.13 for the C123T site reaches the sequence that is comprised of SEQ ID NO.2 and SEQ ID NO.14; The sequence that is comprised of SEQ ID NO.3 and SEQ IDNO.15 for the A101G site reaches the sequence that is comprised of SEQ ID NO.4 and SEQ ID NO.16; The sequence that is comprised of SEQ IDNO.5 and SEQ ID NO.17 for the G118T site reaches the sequence that is comprised of SEQ ID NO.6 and SEQ ID NO.18; The sequence that is comprised of SEQ ID NO.7 and SEQ ID NO.19 for the A77G site reaches the sequence that is comprised of SEQ ID NO.8 and SEQ ID NO.20; The sequence that is comprised of SEQ ID NO.9 and SEQ ID NO.21 for the T139C site reaches the sequence that is comprised of SEQ ID NO.10 and SEQID NO.22; And/or for the sequence that is formed by SEQ ID NO.11 and SEQ ID NO.23 in C288T site and the sequence that is formed by SEQ ID NO.12 and SEQ ID NO.24.
Another object of the present invention provides a kind of Auele Specific Primer for the detection of CYP2B6 gene pleiomorphism.
The technical scheme that realizes above-mentioned purpose is as follows:
A kind of Auele Specific Primer for the detection of CYP2B6 gene pleiomorphism, described specific primer sequence is: for SEQ ID NO.13 and the SEQ ID NO.14 in C123T site; SEQ ID NO.15 and SEQ ID NO.16 for the A101G site; SEQ ID NO.17 and SEQ ID NO.18 for the G118T site; SEQ ID NO.19 and SEQ IDNO.20 for the A77G site; SEQ ID NO.21 and SEQ ID NO.22 for the T139C site; And/or for SEQ IDNO.23 and the SEQ ID NO.24 in C288T site.
Major advantage of the present invention is:
1. the identical rate of the detected result of detection liquid-phase chip provided by the present invention and sequencing is up to 100%, and detects the needed time well below sequencing technologies commonly used, and realistic especially application needs.Prepared CYP2B6 gene pleiomorphism detects liquid-phase chip and has extraordinary signal-noise ratio, and basically there is not cross reaction between designed probe and the anti-tag sequence, choosing and tag sequence label and the specifically combination of ASPE primer of tag sequence label, anti-tag sequence label, can avoid cross reaction, realize the parallel detection of a plurality of pleomorphism sites.
2. the present invention has chosen optimum combination by the design experiences of contriver's long-term accumulation and a large amount of experimental implementation from numerous Auele Specific Primers.The ASPE primer specificity primer of the present invention's design can sensitive be identified the mutational site of target detect specifically, accurately distinguishes the genotype of various types; In same reaction system, between the different Auele Specific Primers, basically do not have cross reaction between the pcr amplification product of Auele Specific Primer and non-target detect, detection specificity is good, and cross reacting rate is lower than 3%; Except detecting Single locus sudden change situation, the also polymorphism situation in a plurality of mutational sites of simultaneously parallel detection, it is consistent to detect effect.
3. detection method step of the present invention is simple, six kinds of pleomorphism sites detect and can finish five amplifications that contain the target sequence of pleomorphism site by a step multiplex PCR, many uncertain factors of existing in the complex operations processes such as repeated multiple times PCR have been avoided, thereby can greatly improve Detection accuracy, embodied accurate while qualitative and quantitative analysis feature.
4. not only to have overcome traditional solid phase chip susceptibility not high in the present invention, and the defective that the repeatability of detected result is poor is improved existing liquid-phase chip technology simultaneously, so that prepared microballoon can be applicable to different test items, has very strong expansion.The fluorescent signal value that detects improves greatly, thereby so that the sensitivity that detects is further enhanced, signal to noise ratio strengthens, and detected result more accurately and reliably.
5. the CYP2B6 gene mutation detection liquid-phase chip among the present invention provides a kind of technical scheme of different designs for the parallel detection of a plurality of sites Multi-genotype, and has produced significant technique effect.Simultaneously, since the technical characterictics such as high-throughput high specific, the demand of more realistic application.Liquid-phase chip technology of the present invention will represent the technology trends that biological target detects.
Embodiment
Embodiment 1CYP2B6 gene pleiomorphism detects liquid-phase chip, mainly includes:
One, ASPE primer
Wild-type and mutant for CYP2B6 gene six kinds of common genotype C123T, A101G, G118T, A77G, T139C and C288T design respectively specific primer sequence.The ASPE primer is comprised of " Tag sequence+specific primer sequence ".The ASPE primer sequence is as shown in the table:
The ASPE primer sequence (Tag sequence+specific primer sequence) of table 1CYP2B6 gene
Every the ASPE primer comprises two parts, and 5 ' end is the specificity tag sequence for anti-tag sequence on the corresponding microballoon, and 3 ' end is mutant or the special primer fragment (as shown in Table 1 above) of wild-type.All ASPE primers are synthetic by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.Every primer after synthetic is mixed with respectively the stock solution of 100pmol/mL with 10mmol/L Tris Buffer.
Two, the coated microballoon of anti-tag sequence
According to designed ASPE Auele Specific Primer fragment, select the tag sequence, reduce to greatest extent between the anti-tag sequence of each microballoon and secondary structure that tag and ASPE Auele Specific Primer fragment may form, corresponding anti-tag sequence is as shown in table 2 on 12 kinds of microballoons numberings of selection and the microballoon:
Corresponding anti-tag sequence on table 2 microballoon numbering and the microballoon
12 kinds of microballoons selecting are coated in the anti-tag sequence on the microballoon available from U.S. Luminex company.Be connected with the spacerarm sequence of 5-10 T between anti-tag sequence and the microballoon, namely add the spacerarm sequence of the preceding paragraph 5-10 T before each anti-tag sequence, the anti-tag sequence is synthetic by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.With synthetic anti-tag sequence sterilization ddH
2O is made into the stock solution of 100nmol/ml.Described spacerarm is for being used for anti-tag and microsphere surface is spaced apart or anti-tag is placed the sequence of hydrophilic environments.By the spacerarm sequence of suitable length is set between anti-tag sequence and microballoon, can reduce sterically hinderedly, improve the efficient of hybridization and the specificity of hybridization.Common spacerarm sequence comprises poly dT, i.e. poly (dT), and oligomerization four polyoxyethylene glycol and (CH2) n spacerarm (n 〉=3) are such as (CH2) 12, (CH2) 18 etc.In addition, if exist poly (dA) to disturb, can also use poly (TTG) as spacerarm.Spacerarm of the present invention is preferably 5-10 T, and the process that microballoon is coated with is as follows:
Get respectively 5 * 10
6The carboxylated microballoon of individual above-mentioned numbering (available from Luminex company) is suspended in the MES solution of 50ul 0.1mol/L (pH4.5), adds the synthetic anti-tag molecule (100nmol/ml) of 10ul.EDC (N-(3-Dimethylaminopropyl-N-ethylcarbodiimide) (available from the Pierce Chemical company) working fluid of preparation 10ng/ml.The EDC working fluid that adds 2.5ul in the microballoon suspension, constant-temperature incubation 30 minutes adds the EDC working fluid of 2.5ul again, and constant-temperature incubation is 30 minutes again.After reaction finished, the Tween-20 washing with 0.02% was once washed once with 0.1% SDS liquid again.The microballoon that is coated with the anti-tag sequence after the washing is resuspended in the Tris-EDTA solution [10mmol/L Tris (pH8.0)] of 100ul, and among the 1mmol/LEDTA, 2-8 ℃ keeps in Dark Place.
Three, amplify the primer of the target sequence that contains the mutational site
For CYP2B6 gene six kinds of common genotype C123T, A101G, G118T, A77G, T139C and C288T, design of amplification primers amplifies respectively five target sequences that contain pleomorphism site to (seeing Table 3).
Table 3 amplifies the primer of the target sequence with pleomorphism site
All primers are synthetic by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.Every primer after synthetic is mixed with respectively the stock solution of 100pmol/mL with 10mmol/L Tris Buffer.
It is as follows to the prescription of the described various solution of detection of sample that embodiment 2 uses embodiment 1 described CYP2B6 gene pleiomorphism to detect liquid-phase chip:
MES damping fluid (pH5.0) prescription (250ml) of 50mM:
2 * Tm hybridization buffer
| Reagent | The source | Final concentration | The consumption of every 250ml |
| MTris-HCl，pH8.0 | SigmaT3038 | 0.2M | 50ml |
| 5MNaCl | Sigma S5150 | 0.4M | 20ml |
| Triton X-100 | Sigma T8787 | 0.16％ | 0.4ml |
Be stored in 4 ℃ after the filtration.
The ExoSAP-IT test kit is available from U.S. USB company.
Biotin labeled dCTP is available from Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.
One, the DNA extraction of sample:
With reference to " molecular cloning " methods involving about DNA extraction, obtain DNA to be detected.
Two, the pcr amplification of testing sample
Design five pairs of primers, one step of multiplex PCR amplifies the five objective sequences that contain respectively CYP2B6 gene six kinds of common genotype C123T, A101G, G118T, A77G, T139C and C288T, wherein, T139C and C288T are positioned at the same amplified production, the product size is respectively 356bp, 235bp, 246bp, 275bp and 384bp, and primer sequence (SEQ ID NO.37-46) is seen shown in the above-mentioned table 3.
At first prepare the multiple PCR primer working fluid: respectively get respectively the primer stock solution 100ul of SEQ ID NO.37-46 in the 1.5ml Eppendorf tube, mix and be the multiple PCR primer working fluid.The multi-PRC reaction system is as follows:
The pcr amplification program is: 95 ℃ of 3min; 94 ℃ of 30s, 56 ℃ of 30s, 72 ℃ of 40s, 30 circulations; 72 ℃ of 10min; 4 ℃ save backup.
Three, the enzyme of PCR product is cut processing
1. get the reacted product of 7.5ul PCR, add 1ul 10 * SAP damping fluid, 1ul SAP enzyme and 0.5ul Exo-I enzyme;
2.37 ℃ hatch 15min, hatch 15min for 80 ℃, the enzyme that deactivation is unnecessary.The product that enzyme is cut after the processing is directly used in follow-up ASPE primer extension reaction.
Four, site-specific primer extension reaction (ASPE)
Utilize the ASPE primer of above-mentioned design to carry out primer extension reaction, in reaction process, mix biotin labeled dCTP, thereby make a plurality of biotin labeling on the reacted product band.
At first prepare the ASPE primer working fluid that mixes: get respectively the corresponding wild-type of gene to be detected and mutant ASPE primer stock solution 10ul in the 1.5ml Eppendorf tube, add 10mmol/L Tris Buffer and mend to 200ul, mix and be ASPE mix primer working fluid.The system of ASPE reaction is as follows:
Response procedures is: 96 ℃ of 2min; 94 ℃ of 30s, 54 ℃ of 1min, 72 ℃ of 2min, 30 circulations; 4 ℃ save backup.
Five, hybridization
According to the design the ASPE primer, the corresponding 12 kinds of microballoons of every group selection (as described in Example 1), every kind of microballoon concentration is 2.5 * 10
5Individual/ml;
2. get respectively the microballoon of every kind of numbering of 1ul in the Eppendorf tube of 1.5ml;
3. microballoon is in 〉=centrifugal the 1-2min of 10000g;
4. supernatant discarded, microballoon is resuspended in 2 * Tm hybridization buffer of 100ul, the vortex mixing;
5. get the above-mentioned microballoon suspension of 25ul in the corresponding hole of 96 hole filter plates, control wells adds the ddH of 25ul
2O;
6. get the ASPE reaction solution of 5-25ul in corresponding hole, use ddH
2O complements to 50ul;
7. encase 96 orifice plates with lucifuge with masking foil, 95 ℃ of 60s, 37C 15min is hatched hybridization;
8. the microballoon after the hybridization is in 〉=centrifugal the 2-5min of 3000g;
9. remove supernatant, microballoon is resuspended in 1 * Tm hybridization buffer of 75ul;
10. microballoon is in 〉=centrifugal the 2-5min of 3000g;
11. microballoon is resuspended in 1 * Tm hybridization buffer of 75ul, adding 15ul concentration is the SA-PE (SA-PE) of 10ug/ml;
12.37 ℃ hatch 15min, on the Luminex instrument, detect.
Six, the result detects and data analysis
The reaction after product detects by Luminex serial analysis instrument.Detected result is shown in table 4, table 5 and table 6.
Fluorescent value (MFI) and data processing there are following requirement:
1. each site need have an allelotrope MFI at least greater than 300 and greater than 10 * PCR negative control MFI;
2.NET MFI=sample MFI-PCR negative control MFI (NET MFI less than 0 with 0 the expression);
3. satisfy the data of above two conditions, calculate sudden change ratio by following formula:
Sudden change ratio=mutant NET MFI ÷ (mutant NETMFI+ wild-type NET MFI)
4. rule of thumb to the sudden change ratio definite threshold (cut-off value) of each detection site, to divide wild-type homozygote, heterozygote and mutant homozygote.
Use present method to detect 20 increments CYP2B6 gene polymorphism sites originally, experimental data meets above-mentioned requirements, therefore can calculate their sudden change ratio.Arranging of threshold value (cut-off value) is as follows: the sudden change ratio range is considered as the wild-type homozygote at 0%-20%; 30%-70% is considered as heterozygote; 80%-100% is considered as the anomaly homozygote.Compare with the liquid-phase chip result with the sequencing detection, calculate the identical rate of classifying method detected result provided by the present invention.Present method detects 20 increments CYP2B6 genotype detection result and the sequencing result rate of coincideing originally and reaches 100%.As seen CYP2B6 gene pleiomorphism provided by the present invention detects liquid-phase chip and can detect exactly CYP2B6 gene polymorphism sites type, and the result is reliable and stable.
One of table 4 pattern detection result (MFI)
Table 5 pattern detection result's (MFI) two
Table 6 sample CYP2B6 transgenation ratio (%)
| Sample number | C123T | A101G | G118T | A77G | T139C | C288T |
| 1 | 3％ | 2％ | 2％ | 1％ | 1％ | 1％ |
| 2 | 2％ | 2％ | 1％ | 2％ | 2％ | 1％ |
| 3 | 2％ | 2％ | 2％ | 2％ | 1％ | 2％ |
| 4 | 1％ | 3％ | 1％ | 1％ | 2％ | 3％ |
| 5 | 2％ | 1％ | 2％ | 1％ | 1％ | 3％ |
| 6 | 98％ | 2％ | 1％ | 1％ | 1％ | 1％ |
| 7 | 2％ | 3％ | 1％ | 2％ | 2％ | 2％ |
| 8 | 3％ | 2％ | 2％ | 2％ | 1％ | 98％ |
| 9 | 1％ | 2％ | 50％ | 1％ | 2％ | 1％ |
| 10 | 3％ | 2％ | 1％ | 2％ | 2％ | 2％ |
| 11 | 1％ | 2％ | 1％ | 2％ | 1％ | 1％ |
| 12 | 1％ | 2％ | 2％ | 2％ | 2％ | 2％ |
| 13 | 2％ | 3％ | 1％ | 2％ | 1％ | 2％ |
| 14 | 2％ | 2％ | 1％ | 97％ | 1％ | 1％ |
| 15 | 2％ | 3％ | 2％ | 2％ | 1％ | 1％ |
| 16 | 1％ | 98％ | 2％ | 2％ | 2％ | 2％ |
| 17 | 2％ | 2％ | 1％ | 2％ | 2％ | 1％ |
| 18 | 2％ | 2％ | 2％ | 2％ | 1％ | 1％ |
| 19 | 1％ | 1％ | 2％ | 1％ | 1％ | 2％ |
| 20 | 1％ | 2％ | 2％ | 2％ | 1％ | 1％ |
Table 7 sample CYP2B6 gene mutation type analytical results
| Catalogue number(Cat.No.) | The liquid-phase chip detected result | Sequencing result |
| 1 | Wild-type | Wild-type |
| 2 | Wild-type | Wild-type |
| 3 | Wild-type | Wild-type |
| 4 | Wild-type | Wild-type |
| 5 | Wild-type | Wild-type |
| 6 | 123TT | 123TT |
| 7 | Wild-type | Wild-type |
| 8 | 288TT | 288TT |
| 9 | 118GT | 118GT |
| 10 | Wild-type | Wild-type |
| 11 | Wild-type | Wild-type |
| 12 | Wild-type | Wild-type |
| 13 | Wild-type | Wild-type |
| 14 | 77GG | 77GG |
| 15 | Wild-type | Wild-type |
| 16 | 101GG | 101GG |
| 17 | Wild-type | Wild-type |
| 18 | Wild-type | Wild-type |
| 19 | Wild-type | Wild-type |
| 20 | Wild-type | Wild-type |
The liquid-phase chip of the ASPE primer that embodiment 3 is different is to the detection of CYP2B6 gene polymorphism sites
One, the design (selection of Tag sequence and Anti-Tag sequence) of liquid-phase chip preparation
Detect liquid-phase chip as example take CYP2B6 Gene A 101G and T139C site mutation, respectively for the wild-type of A101G and T139C and the specific primer sequence of mutant design ASPE primer 3 ' end, the Tag sequence of ASPE primer 5 ' end then is selected from SEQ ID NO.1-SEQ ID NO.12, accordingly, the anti-tag sequence with corresponding tag sequence complementary pairing that is coated on the microballoon is selected from SEQ ID NO.25-SEQ ID NO.36.Specific design is shown in following table (table 8).Synthetic, the coated microballoon of anti-tag sequence of ASPE primer, amplimer, detection method are described like embodiment 1 and embodiment 2.
The design of table 8 liquid-phase chip preparation
Two, sample detection
Adopt the liquid-phase chip of above-mentioned design preparation, by embodiment 2 described testing processes and method sample 21-40 is detected, detected result is as follows:
Table 9 pattern detection result and Polymorphism Analysis
Table 10 pattern detection result and Polymorphism Analysis
Other is for the liquid-phase chip in different mutational sites, and the ASPE primer uses different Tag sequences, and its result is still reliable and stable, and concrete data are omitted.And the ASPE primer is when selecting among the embodiment 1 collocation of tag sequence and specific primer sequence, and effect better (signal to noise ratio is better) is referring to present embodiment test group 2 and test group 5.Other different tag sequences and specific primer sequence collocation, with coming to the same thing of embodiment 2 and present embodiment, concrete data are omitted.
The selection of embodiment 4CYP2B6 gene pleiomorphism detection specificity primer sequence
One, the design (selection of wild-type and mutant specific primer sequence) of liquid-phase chip preparation
Pleomorphism site take CYP2B6 gene C 123T and G118T detects liquid-phase chip as example, take the forward or backwards complementary sequence of this place, mutational site target sequence as template, respectively for the wild-type of C123T and G118T and the specific primer sequence of mutant design ASPE primer 3 ' end, comprise preferred specific primer sequence and 2 alternative specific primer sequences in the embodiment of the invention 1, as shown in table 9.Wherein,
Interior base is pleomorphism site.
Table 9 specific primer sequence
Pleomorphism site take CYP2B6 gene C 123T and G118T detects liquid-phase chip as example, select different specific primer sequences for C123T and G118T, the Tag sequence of ASPE primer 5 ' end then is fixed as the best effect sequence among the embodiment 1, and select with it corresponding anti-tag sequence, specific design is shown in following table (table 10).Synthetic, the coated microballoon of anti-tag sequence of ASPE primer, amplimer, detection method are described like embodiment 1 and embodiment 2.
Two of the design of table 10 liquid-phase chip preparation
Two, sample detection
Adopt the liquid-phase chip of above-mentioned design preparation, by embodiment 2 described testing processes and method sample 41-60 is detected, detected result is as follows:
Table 11 pattern detection result and Polymorphism Analysis
Table 11 pattern detection result and Polymorphism Analysis
By present embodiment as seen, when the ASPE primer was selected among the embodiment 1 collocation of specific primer sequence and tag sequence, effect better (signal to noise ratio is better) was referring to present embodiment test group 7 and test group 10.Other derives from different specific primer sequences and the collocation of tag sequence of the forward or backwards complementary sequence of place, target detect site sequence, with coming to the same thing of embodiment 2 and present embodiment, namely still be that the specific primer sequence described in the embodiment 2 is better from different tag sequence arranging effects, concrete data are omitted.Other is for multiple specific primer sequence and the collocation of tag sequence in different mutational sites, with coming to the same thing of embodiment 2 and present embodiment, namely embodiment 1 selected Auele Specific Primer has better signal to noise ratio, it is also better to detect effect, and concrete data are omitted.
More than be for the specifying of possible embodiments of the present invention, but this embodiment limits claim of the present invention, allly do not break away from the equivalence that skill spirit of the present invention does and implement or change, all should be contained in the claim of the present invention.
Claims (6)
1. a CYP2B6 gene pleiomorphism detects liquid-phase chip, it is characterized in that, includes:
(A). the wild-type that designs respectively for the different pleomorphism sites of CYP2B6 gene and the ASPE primer of mutant pair: every ASPE primer is comprised of the tag sequence of 5 ' end and 3 ' the end specific primer sequence for the goal gene pleomorphism site, and described specific primer sequence is: for SEQ ID NO.13 and the SEQ ID NO.14 in C123T site; SEQ ID NO.15 and SEQ ID NO.16 for the A101G site; SEQ ID NO.17 and SEQ ID NO.18 for the G118T site; SEQ ID NO.19 and SEQ ID NO.20 for the A77G site; SEQ ID NO.21 and SEQ ID NO.22 for the T139C site; And/or for SEQ ID NO.23 and the SEQ ID NO.24 in C288T site; Described tag sequence is selected from SEQ ID NO.1～SEQ IDNO.12:
(B). anti-tag sequence microballoon coated, that have the different colours coding is arranged, also be provided with the spacerarm sequence in the middle of described anti-tag sequence is connected with microballoon; Described anti-tag sequence is selected from SEQ ID NO.25～SEQ ID NO.36, and described anti-tag sequence can be correspondingly with (A) in selected tag sequence complementary pairing;
(C). be used for amplifying the primer that needs target sequence detection, that have corresponding pleomorphism site.
2. CYP2B6 gene pleiomorphism according to claim 1 detects liquid-phase chip, it is characterized in that described amplimer is: for SEQ ID NO.37 and the SEQ ID NO.38 in C123T site; SEQ ID NO.39 and SEQ IDNO.40 for the A101G site; SEQ ID NO.41 and SEQ ID NO.42 for the G118T site; SEQ ID NO.43 and SEQ ID NO.44 for the A77G site; And/or for SEQ ID NO.45 and the SEQ ID NO.46 in T139C, C288T site.
3. CYP2B6 gene pleiomorphism according to claim 1 detects liquid-phase chip, it is characterized in that described ASPE primer is: the sequence that is comprised of SEQ ID NO.1 and SEQ ID NO.13 for the C123T site reaches the sequence that is comprised of SEQ ID NO.2 and SEQ IDNO.14; The sequence that is comprised of SEQ ID NO.3 and SEQ ID NO.15 for the A101G site reaches the sequence that is comprised of SEQ IDNO.4 and SEQ ID NO.16; The sequence that is comprised of SEQ ID NO.5 and SEQ ID NO.17 for the G118T site reaches the sequence that is comprised of SEQ ID NO.6 and SEQ ID NO.18; The sequence that is comprised of SEQ ID NO.7 and SEQID NO.19 for the A77G site reaches the sequence that is comprised of SEQ ID NO.8 and SEQ ID NO.20; The sequence that is comprised of SEQID NO.9 and SEQ ID NO.21 for the T139C site reaches the sequence that is comprised of SEQ ID NO.10 and SEQ ID NO.22; And/or for the sequence that is formed by SEQ ID NO.11 and SEQ ID NO.23 in C288T site and the sequence that is formed by SEQ ID NO.12 and SEQ IDNO.24.
4. CYP2B6 gene pleiomorphism according to claim 1 detects liquid-phase chip, it is characterized in that,
(A). described ASPE primer is: the sequence that is comprised of SEQ ID NO.1 and SEQ ID NO.13 for the C123T site reaches the sequence that is comprised of SEQ ID NO.2 and SEQ ID NO.14; The sequence that is comprised of SEQ ID NO.3 and SEQ IDNO.15 for the A101G site reaches the sequence that is comprised of SEQ ID NO.4 and SEQ ID NO.16; The sequence that is comprised of SEQ IDNO.5 and SEQ ID NO.17 for the G118T site reaches the sequence that is comprised of SEQ ID NO.6 and SEQ ID NO.18; The sequence that is comprised of SEQ ID NO.7 and SEQ ID NO.19 for the A77G site reaches the sequence that is comprised of SEQ ID NO.8 and SEQ ID NO.20; The sequence that is comprised of SEQ ID NO.9 and SEQ ID NO.21 for the T139C site reaches the sequence that is comprised of SEQ ID NO.10 and SEQID NO.22; Reach the sequence that is formed by SEQ ID NO.12 and SEQ ID NO.24 with the sequence that is formed by SEQ ID NO.11 and SEQ ID NO.23 for the C288T site;
(B). anti-tag sequence microballoon coated, that have the different colours coding is arranged, also be provided with the spacerarm sequence in the middle of described anti-tag sequence is connected with microballoon; Described anti-tag sequence is selected from SEQ ID NO.25～SEQ ID NO.36, and described anti-tag sequence can be correspondingly with (A) in selected tag sequence complementary pairing;
(C). for SEQ ID NO.37 and the SEQ ID NO.38 in C123T site; SEQ IDNO.39 and SEQ ID NO.40 for the A101G site; SEQ ID NO.41 and SEQ ID NO.42 for the G118T site; SEQ ID NO.43 and SEQ ID NO.44 for the A77G site; With SEQ ID NO.45 and the SEQ ID NO.46 for T139C, C288T site.
5. each described CYP2B6 gene pleiomorphism detects liquid-phase chip according to claim 1-4, it is characterized in that described spacerarm is 5-10 T.
6. one kind is used for the Auele Specific Primer that the CYP2B6 gene pleiomorphism detects, and it is characterized in that described specific primer sequence is: for SEQ ID NO.13 and the SEQ ID NO.14 in C123T site; SEQ ID NO.15 and SEQ IDNO.16 for the A101G site; SEQ ID NO.17 and SEQ ID NO.18 for the G118T site; SEQ ID NO.19 and SEQ ID NO.20 for the A77G site; SEQ ID NO.21 and SEQ ID NO.22 for the T139C site; And/or for SEQID NO.23 and the SEQ ID NO.24 in C288T site.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110219244.5A CN102912007B (en) | 2011-08-02 | 2011-08-02 | CYP2B6 gene polymorphism detection specific primers and liquid chip |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110219244.5A CN102912007B (en) | 2011-08-02 | 2011-08-02 | CYP2B6 gene polymorphism detection specific primers and liquid chip |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102912007A true CN102912007A (en) | 2013-02-06 |
| CN102912007B CN102912007B (en) | 2014-09-24 |
Family
ID=47610583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110219244.5A Expired - Fee Related CN102912007B (en) | 2011-08-02 | 2011-08-02 | CYP2B6 gene polymorphism detection specific primers and liquid chip |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102912007B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101487052A (en) * | 2009-02-24 | 2009-07-22 | 广州益善生物技术有限公司 | Liquid phase chip for CYP2C9 and CYP2C19 gene mutation detection and detecting method thereof |
| CN101565749A (en) * | 2009-04-15 | 2009-10-28 | 广州益善生物技术有限公司 | CYP2C19 and ABCB1 gene SNP detection liquid-phase chip and detection method thereof |
-
2011
- 2011-08-02 CN CN201110219244.5A patent/CN102912007B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101487052A (en) * | 2009-02-24 | 2009-07-22 | 广州益善生物技术有限公司 | Liquid phase chip for CYP2C9 and CYP2C19 gene mutation detection and detecting method thereof |
| CN101565749A (en) * | 2009-04-15 | 2009-10-28 | 广州益善生物技术有限公司 | CYP2C19 and ABCB1 gene SNP detection liquid-phase chip and detection method thereof |
Non-Patent Citations (4)
| Title |
|---|
| CORINE EKHART ET AL.: "Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa", 《BRITISH JOURNAL OF CLINICAL PHARMACOLOGY》 * |
| HIROYUKI GATANAGA ET AL.: "Successful Efavirenz Dose Reduction in HIV Type 1–Infected Individuals with Cytochrome P450 2B6 *6 and *26", 《CLINICAL INFECTIOUS DISEASES》 * |
| LEVRAN O ET AL.: "CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction", 《ADDICTION BIOLOGY》 * |
| M ROTGER ET AL.: "Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV-infected Individuals", 《CLINICAL PHARMACOLOGY & THERAPEUTICS》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102912007B (en) | 2014-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103374609B (en) | ABO gene mutation detection specific primers and liquid chip | |
| CN102912002B (en) | ABCB2 gene polymorphism detection specific primers and liquid chip | |
| CN102191337B (en) | Specific primers and liquid phase chip for detecting polymorphism of cyckin-dependent kinase 5 regulatorysubunit-associated protein 1-like 1(CDKAL1) gene | |
| CN102994621A (en) | PTPN11 gene mutation detection specificity primer and liquid chip thereof | |
| CN102304563B (en) | Specific primers and liquid phase chip for polymorphic detection of fat mass and obesity associated (FTO) gene | |
| CN102912007B (en) | CYP2B6 gene polymorphism detection specific primers and liquid chip | |
| CN102181573B (en) | Specific primers and liquid-phase chip for detection of KITLG gene | |
| CN102912006B (en) | CYP2A6 gene polymorphism detection specific primers and liquid chip | |
| CN102912005B (en) | CYP2C8 gene polymorphism detection specific primers and liquid chip | |
| CN102191336B (en) | MYC gene single nucleotide polymorphism (SNP) detection specific primer and liquid-phase chip | |
| CN102952866B (en) | Specific primer and liquid chip for detecting polymorphism of DPYD (dihydropyrimidine dehydrogenase) gene | |
| CN103031365A (en) | ATM gene mutation detection specific primer and liquid chip | |
| CN102952867B (en) | Specific primer and liquid chip for detecting polymorphism of SLC22A6 gene | |
| CN102952868B (en) | Specific primer and liquid chip for detecting polymorphism of SLC15A2 gene | |
| CN102952873B (en) | Specific primer and liquid chip for detecting polymorphism of NAT1 (N-acetyltransferase 1) gene | |
| CN102952870B (en) | Specific primer and liquid chip for detecting polymorphism of SLC22A2 gene | |
| CN102888444B (en) | Factor II and Factor V genetic polymorphism detection specific primer and liquid-phase chip | |
| CN102191335B (en) | Specific primer and liquid-phase chip for SNP (single nucleotide polymorphism) detection of PIGU (phosphatidylinositol glycan anchor biosynthesis, class U) genes | |
| CN102994625B (en) | PIK3R1 gene mutation detection specificity primer and liquid chip thereof | |
| CN102952872B (en) | Specific primer and liquid chip for detecting polymorphism of SLCO1B3 gene | |
| CN103374607A (en) | ABCC (ATP (adenosine triphosphate)-binding cassette, sub-family C)1 gene mutation detection specific primers and liquid chip | |
| CN102952874B (en) | Specific primer and liquid chip for detecting polymorphism of SLC22A1 gene | |
| CN102304566B (en) | Specific primers and liquid phase chip for polymorphic detection of human hedgehog interacting protein (HHIP) gene | |
| CN102912008B (en) | ABCG2 gene polymorphism detection specific primer and liquid phase chip | |
| CN102952869B (en) | Specific primer and liquid chip for detecting polymorphism of SLCO1B1 gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Five 510663 Guangdong city of Guangzhou province Guangzhou Science City Moon Road No. 80, Guangzhou technology innovation base B, C Applicant after: Surexam Biological Technology Co., Ltd. Address before: Five 510663 Guangdong city of Guangzhou province Guangzhou Science City Moon Road No. 80, Guangzhou technology innovation base B, C Applicant before: Guangzhou Yishan Biotechnology Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: GUANGZHOU YISHAN BIOTECHNOLOGY CO., LTD. TO: SUREXAM BIOTECHNOLOGY CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140924 Termination date: 20150802 |
|
| EXPY | Termination of patent right or utility model |